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OlJrcdw:. The management
of mural thrombus complicating
acute anterior myocardial tnf retiou remains
controversial In part
beamle of the weal size
of studies on this topic . We performed a
of published studies to address three questions
:
1) What b the embolic risk of mural thrombi after myocardial
ishretioa? 2) What is the impact of systemic antkoagulatlon In
reducing the embolic risk of mural
thrombi? 3) What Is the impact
of systemic anticoagulation, thrmbolytic therapy and andplatekt
therapy In preventing mural thrombus formation?
Mesons. Studies were identified by a computerized and moo
.
ualMarch. astd were Included If they were published In manuscript
forte In due 1£e~lish~l>nlguage literature
. Pooling of data was
performed by
"dog
the Mantel-Haeusad odds ratio and an
event rate dillbrence by the method of DerSimonlan
and Laird .
Ru n k The odds ratio for increased risk of emboli In the
presence of echocardiographlcally demonstrated mural thrombus
III stwdes, 856 patients) was 5
.45 (95% confidence Interval (CI)
3.42 to 9.83), and the event rate difference as 0 .09 (95% CI 0 .03
to 0.14). The odds redo of autkoaguladon versus no anticoagala.
lion In preventing embolizalion (seven studies, 270 patients) was
Left ventricular mural thrombus has been frequently identi-
fied at autopsy (1-5) and by two-dimensional echocardiogra-
phy (6-16) in patients with acute anterior myocardial infarc-
tion
. However, mural thrombus formation in inferior
myocardial infarctions is rare (6,7). Overall. 1 .5% to 3.6% of
patients with acute myocardial infarction have a complicat-
ing stroke, often thought to be embolic from a mural throm-
bus (17,18). Despite much recent
investigation (19,20), there
is no Consensus on appropriate strategies for screening and
treating mural thrombi
. Much of the controversy arises from
apparently divergent estimates of the frequency of embolic
complications from mural thrombi and on the effects of
antilhrombotic treatment in preventing the formation or the
embolization of mural thrombi
. The contradictory results
arise, in part, from the small size of the individual studies .
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0.14
(95% CI 0.04 to 0 .52) with an event rate difference of -0 .33
(95% CI --0.50 to -0.16). The odds ratio of anticoagulation
versus control in preventing mural thrombus formation (four
studies, 307 patients) was 0.32 (95% CI 0.20 to 0
.52), and the
event rate difference was -0
.19 (95% CI -0.09 to -0.28). The
odds ratio for thrombolytic therapy in preventing mural thrombus
(six studies, 390 patients) was 0
.48 (95% CI 0.29 to 0.79) with an
event rate difference of -0
.16 (95% Cl 0 .10 to -0.42), whereas
for antiplatelet agents (two studies, 112 patients) the odds ratio
was 1.43 (95% CI 0.04 to 56.8) with an event rate difference d
0.16 (95% C1-0.20 to 0.52).
Conclusions. This analysis supports the hypotheses that 1)
mural thrombus after myocardial infarction poses a significantly
Increased risk of embollzatlon, 2) the risk of embolization Is
reduced by systemic anticoagulation, and 3) anticoagulation can
prevent mural thrombus formation. Thrombolytic therapy may
prevent mural thrombus formation, but evidence for a similar
benefit of antiplatelet therapy Is lacking .
(J Am Coil Cardiol 1993,22:1004-9)
We therefore performed a meta-analysis to reconcile the
apparently conflicting data for the following three questions :
1) What is the relative risk of embolic events in patients
with echocardiographically demonstrated mural thrombus
after an acute anterior myocardial infarction compared with
those without thrombus? 2) What is the effect of systemic
anticoagulation in reducing embolic complications of mural
thrombi? 3) What is the im ;:~;1 = : ~ ctrs.c antic agulation,
thrombolytic therapy and antiplatelet therapy in preventing
mural thrombus formation?
Methods
Studies were identified by means of a computerized
literature search (MEDLINE, BRS Colleague) supple-
mented by a manual review of references cited in the
bibliographies of these studies. Studies were included for
analysis if they were published in manuscript form in
English-language peer-reviewed journals and either included
only patients with acute anterior Q wave myocardial infarc-
tion or presented data in a manner that permitted separation
of patients with anterior versus inferior myocardial infarc-
tion
. Only data on patients with anterior myocardial infarc-
0735-1097193156.00
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Lion were included in the analyses . Furthermore, studies
were required to use two-dimensional echocardiography to
identify left ventricular thrombus . In the therapeutic trials
we required studies to simultaneously evaluate treated and
control groups . Studies published only in abstract form or in
books or monographs not subject to peer review, studies
using historical controls and studies combining anterior and
inferior infarctions were excluded .
For each study we constructed a 2 x 2 contingency table,
allowing us to calculate an event rate difference, an odds
mtio, and a 95% confidence interval for each of these
variables . Pooling of data was undertaken by calculating the
Mantel-Haenszel odds ratio with the Robins, Greenland and
Breslow estimator of variance (21) . We also calculated a
pooled event rate difference by the method of DerSimonian
and Laird (22) . Besides differing in units of measure, in the
presence of heterogeneity, the DerSimonian and Laird
method yields more conservative statistical tests of the
pooled treatment effect with relatively wider confidence
intervals than does the Mantel-Haenszel method . As a test of
heterogeneity, we calculated a
Q
statistic (22) . A statistically
significant result of the
Q
statistic suggests statistical heter-
ogeneity among the studies included for analysis .
The trials included for analysis were reported over a span
of II years . We examined whether improvements in
echocardiographic technology during these years affected
the reported outcomes by studying the temporal trends of
two variables : the reported incidence rate of mural thrombi
and the reported treatment effect .
Results
The embolic risk of mural thrombus (Fig . 1) . Eleven
studies (6-16) enrolling a total of 856 patients were included
in the analysis . Individually . 10 of the I I studies reported
that patients with echocardiographically demonstrated mural
thrombus were at higher risk of embolic events than patients
without mural thrombi . However, nine of the studies were
sufficiently small that their 95% confidence intervals (C)
were consistent with either an increased or decreased risk of
embolization . The pooled odds ratio for increased risk of
embolization for the I I studies was 5 .45 (95% Cl : 3 .02 to
9.83), and the pooled event rate difference was 0 .09 (95%
confidence interval : 0.03 to 0.14) . Both of the pooling
methods were consistent with the hypothesis that mural
thrombus poses an increased risk for embolic complications
after a myocardial infarction . The Q statistic was 18 .6 (p <
0.01), suggesting heterogeneity among the studies included
for analysis .
Does anticoagulation reduce the embolic risk of mural
thrombi? (Fig. 2). Seven studies (6-8,16,23-25) enrolling a
total of 270 patients were pooled in this analysis . Although
all seven studies presented data suggesting that systemic
anticoagulation of patients with mural thrombi reduces em-
bolic complications, this trend reached statistical signifi-
cance in only three of the trials . The odds ratio was 0.14
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Figure 1. Odds ratios (dots) and 95% confidence intervals
(bars) for
I I studies (6-16) addressing the embolic risk of echocardiographi-
cally demonstrated mural thrombus after anterior myocardial infarc-
tion. An odds ratio >1 .0 indicates an increased risk of embolism
with mural thrombi .
(95% CI 0.04 to 0 .52), and the pooled event rate difference
was -0.33 (95% Cl -0.50 to -0.16), supporting the hypoth-
esis that anticoagulation reduces embolic events . The Q
statistic was 18 .8 (p < 0 .01) .
Does antithrombotic therapy prevent mural thrombus for.
mation? (Fig. 3 to 5). Ant; coagulant therapy . Four studies
(I1,12,14,26) enrolling 307 patients were included in this
analysis . Three of the four studies revealed a trend in favor
of anticoagulation . In one of these studies the trend was
statistically significant (Fig . 3). The odds ratio was 0.32
(95% CI 0.20 to 0 .52), and the pooled event rate difference
was -0.19 (95% Cl -0.09 to -0.28), both suggesting a
significant decrease in mural thrombus formation with anti-
coagulation . The Q statistic was 3 .4 (p = NS) .
Thrombolytic therapy (Fig . 4). Six studies (16,27-31)
enrolling 390 patients were pooled . Five of the six studies
reported a trend in favor of thrombolysis, with one achieving
statistical significance . However, the confidence intervals of
all six studies encompassed the possibility that thrombolytic
therapy was associated with a reduction of risk of mural
thrombus formation . The pooled odds ratio was 0
.48 (95% CI
0.29 to 0.79), suggesting a significant decrease in the inci-
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Figure 2. Odds ratios (dots) and 95% confidence intervals (bars) for
seven studies (6-9,16,23-25) addressing the efficacy of systemic
anticoagulation in reducing the embolic risk of mural thrombi after
anterior myocardial infarction .
dance of mural thrombi . The event rate difference was -0.16
(95% C10.10 to -0.42). This result is compatible with the
hypothesis that thrombolytic agents reduce the incidence of
mural thrombus but does not achieve statistical significance .
The Q statistic was 15 .1 (p < 0.01) .
Antiplatelet therapy (Fig . 5). Two studies (32.33) enroll-
ing 112 patients were pooled with an odds ratio of 1 .43
(95% CI 0.04 to 56.8) and an event rate difference of 0.16
(95% CI -0.20 to 0.52), bt .th failing to demonstrate a
significant decrease in mural thrombus with antiplatelet
therapy. The Q statistic was 2.8 (p = NS).
Tte enl tt s. Neither the reported incidence of mu-
ral thrombi in untreated control subjects (mean 38 ± 12%,
range 19% to 68%) nor any of the treatment effects outlined
earlier demonstrated a significant relation to the year of
publication of the report .
Discussion
A randomized controlled, blinded, prospective clinical
trial is widely regarded as the most appropriate means of
addressing a specific clinical question. However, when rel-
atively small studies are undertaken, their small size leads to
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Figure 3
. Odds ratios (dots) and 95% confidence intervals (bars) for
four studies (11,12,14,26) addressing the efficacy of systemic anti-
coagulation in reducing the incidence of mural thrombi after anterior
myocardial infarction
.
a low statistical power to detect differences between groups
of patients, This limitation can result in apparently conflict-
ing results among a group of small studies addressing the
same question . By pooling data from a number of studies, a
meta-analysis may allow these conflicting results to he
resolved in a formal, quantitative manner . In the presence of
statistical heterogeneity, as in the case of several of the
present analyses, the results of a meta-analysis need to he
interpreted cautiously .
Our meta-analysis demonstrated that the risk of embolic
complications in patients with echocardiographically dem-
onstrated mural thrombus after acute anterior myocardial
infarction is increased fivefold over that in patients without
mural thrombus . The absolute increase in risk is approxi-
mately 9% (2% risk in patients without thrombus, I I% risk in
patients with thrombus). Of the I1 studies included in our
analysis, only I suggested that mural thrombus posed no
added risk of embolization and concluded that anticoagula-
tion in these patients is not justified (15). However, the
confidence interval of this study included the possibility that
mural thrombus does pose an excess risk . The apparent lack
of excess risk in this one small study may be attributable to
a beta error. By pooling the I I studies, the power is increased,
so that the increased embolic risk becomes evident .
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figure 4. Odds ratios (dots) and 95% confidence intervals (bars) for
six studies (16,27-31) addressing the efficacy of thrombolytic ther-
apy in reducing the incidence of mural thrombi after anterior
myocardial infarction .
A meta-analysis of anticoagulation administered indis-
criminately to all patients with a diagnosis of acute myo-.ar-
dial infarction has shown a reduced incidence of stroke (17).
Because patients with acute anterior myocardial infarction
have been identified as being at greatest risk of mural
thrombus formation (6,7), it would seem logical that anti-
coagulation in this setting would prove particularly benefi-
cial . The results of our current meta-analysis support the
hypothesis that systemic anticoagulation in patients with
echocardiographically demonstrated mural thrombus re-
duces the incidence of embolic events. Embolism occurred
eight times more frequently in untreated patients, resulting
in an absolute risk difference of 33%.
In devising a strategy of screening for and treating mural
thrombus, one is confronted with a dilemma of timing of
diagnostic and therapeutic maneuvers . Mural thrombi can
form as late as 8 to 10 days after myocardial infarction
(19,32,34). Thus, maximal sensitivity for echocardiography
would be achieved by delaying this study until the 10th day
after myocardial infarction. However: because the risk of
embolism is greatest in the 1st week after infarction
(18,19,34), a strategy of delaying therapy until the echocar-
diographic study is performed may prove futile. Further-
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Figure 5. Odds ratios (dots) and 95% confidence intervals (bars) for
two studies (32,33) addressing the efficacy of antiplatelet ageits in
reducing the incidence of mural thrombi after anterior myoc irdial
infarction .
more, the absence of an echocardiographically demonstrated
thrombus does not confer absolute protection against embo-
lism. In our pooled analysis, 24% of instances of embolism
occurred in patients without mural thrombi and, conversely,
2.2% of patients without mural thrombi had embolism .
Therefore, any strategy relying on the echocardiographic
identification of mural thrombi cannot be uniformly effective
in preventing embolism. Recently, Delemarre et al. (35)
demonstrated that abnormal apical flow patterns identified
by Doppler echocardiography within the 1st 24 h after
myocardial infarction accurately identified patients at risk of
subsequent mural thrombus formation with no cases of false
negative examinations . If these findings are confirmed by
additional investigations, Doppler How studies may emerge
as an effective means of early identification of patientss who
should receive anticoagulation . To further refine the risk
stratification of patients with mural thrombi, several studies
(13,36-39) have examined the relation between the morpho-
logic characteristics of the mural thrombus and embolic risk .
Although thrombus protuberance and mobility
identify a
group of patients at particularly high risk of embolism . ',.' he
absence of these characteristics does not preclude the need
for anticoagulation. Up to 40% of instances of embolism
I	I
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occur in patients whose thrombi are neither protuberant nor
mobile (13).
In addition, no study has examined whether a
strategy of providing selective anticoagulation only for pa-
tients with mobile or protuberant thrombi is effective . At
present it seems prudent to treat all patients with identifiable
mural thrombi with anticoagulation .
Our meta-analysis supports a role for systemic anticoag-
ulation in preventing mural thrombus formation after an acute
anterior myocardial infarction. Evidence for a similar benefit of
antiplatelet agents is lacking at present
. Thrombolytic agents
could be expected to prevent mural thrombi through direct
antithrombotic effects, and by preserving the viability of
myocardium and preventing wall motion abnormalities .
Our analysis of the impact of thrombolysis revealed a
statistically significant result in terms of the odds ratio
calculation, but the trend favoring thrombolysis by the
method of DerSimonian and Laird (22) failed to reach
statistical significance. However, scrutiny of the data on
thrombolytic therapy reveals that the failure of the trend in
favor of thrombolysis to reach statistical significance is
Imply due to a single outlier study. Pragmatically, this issue
may not be of major importance. Thrombotysis is under-
taken with the primary goal of achieving coronary artery
patency, rather than preventing mural thrombi . Further-
more, current practice usually involves the administration of
systemic anticoagulation after thrombolysis to prevent reoc-
elusion of the coronary artery . Several studies (40,41) of
examining the duration of anticoagulation after thrombolytic
therapy for myocardial infarction have suggested that 24-h
regimens of anticougulation are as effective as longer regi-
mens in preventing recurrent myocardial ischemia . How-
ever, on the basis of considerations of the salutary effects of
anticoagulation in preventing mural thrombus formation and
embolic events, a longer regimen may be advocated .
Lira ono of the study. Pooling of data from different
trials may obscure important differences in the designs of the
trials . Assessment of heterogeneity with methods such as the
calculation of the Q statistic addresses the issue of statistical
heterogeneity among the studies pooled but not method-
ologic heterogeneity. Ideally, reported treatment outcome
could be analyzed as a function of a givct, meti.odologic
variable, such as intensity of treatment, to examine whether
the differences in Methodology have a material impact on the
treatment result (42) . However, for most of the methodologic
variables that could conceivably influence the treatment out-
comes in our meta-analysis, insufficient data were provided
in the individual reports to undertake such an analysis .
During the 19fiOs, significant improvements in echocar-
diogtaphic technology may have affected the results of the
trials included in the present analysis. However, all of the
studies utilized two-dimensional echocardiography, and we
were unable to demonstrate a temporal trend either for the
reported incidence of mural thrombus or for the reported
therapeutic effect,
Another important methodologic difference was in the
timing of echocardiography . As previously discussed, mural
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thrombi can form at various times during the 1st 10 days
after myocardial infarction . Thus, the maximal sensitivity for
detecting mural thrombus would be achieved by performing
serial echocardiographic studies throughout this period . Few of
the studies incorporated this strategy, and details of the
timing of echocardiography were absent in several reports .
Differences in the assessment of anticoagulation could
also have affected the reported results, including differences
in the assays used to assess anticoagulation, as well as the
degree of anticoagulation that was pursued. None of the
trials reported data on the frequency of adequate or inade-
quate anticoagulation among treated patients . Although the
importance of the standardized International Normalized
Ratio method for reporting prothrombin times has been
advocated for nearly a decade (43), this has achieved wide-
spread attention only recently (44) and was not incorporated
by any of the trials included in our analysis .
Another source of heterogeneity among the thrombolytic
trials and antiplatelet trials was the use of different therapeu-
tic agents in the various trials . However, a recent study from
the GISSI-2 investigators (45) revealed no difference in risk
of mural thrombus between patients receiving streptocinase
or tissue plasminogen activator .
The morphologic characteristics predicting a high em-
bolic risk were only rarely described in the studies included
in our analysis. Therefore, we could not analyze the impact
of this variable on outcome. However, as mentioned, this
issue may not be of clinical importance because there are no
available data to support the hypothesis that withholding
anticoagulant therapy from patients with nonprotuberant,
nonnubile thrombi is a sound strategy .
One limitation in our analysis of antiplatelet therapy was
the possibility of a beta-error . To achieve 90% certainty of
detecting a 50% reduction in mural thrombus formation by
antiplatelet agents (a treatment effect similar in magnitude to
those of anticoagulation and thrombolysis), there would need
to be 254 patients in the pooled analysis or approximately
double the number we had . Therefore, we cannot confidently
conclude that antiplatelet therapy is with or without benefit .
Conclusions. The results of this meta-analysis support
the hypothesis that the presence of an echocardiographically
demonstrated mural thrombus after an acute anterior myo-
cardial infarction poses a significantly increased risk of
embolization. They also support a role for systemic antico-
agulation in reducing both the incidence of mural thrombi
after acute myocardial infarction and the risk of emboliza-
lion. Thrombolytic agents may be effective in reducing the
incidence of mural thrombi, but evidence for a similar benefit
of antiplatelet agents is lacking .
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